UNITED BIOSOURCE ACQUIRES METAWORKS, INC

January 17, 2006

Applied Clinical Trials

United BioSource Corporation (UBC) today announced the acquisition of MetaWorks, Inc., a leading provider of systematic reviews and meta-analyses to inform development, marketing, and regulatory decision-making regarding health care products and services.

Bethesda, MD – January 17, 2006 – United BioSource Corporation (UBC) today announced the acquisition of MetaWorks, Inc., a leading provider of systematic reviews and meta-analyses to inform development, marketing, and regulatory decision-making regarding health care products and services. The acquisition is part of the UBC strategy of building integrated capabilities to meet growing demand by the pharmaceutical, biotech, medical device and diagnostics sectors for evidence-based product development and commercialization services.

MetaWorks, Inc, provides an array of clinical data products and scientific consulting services to aid the development and commercialization of drugs, devices, diagnostics, and procedures. The company is a world leader in systematic literature reviews of clinical data and the application of complex statistical methods, such as meta-analysis. MetaWorks' database assets include MetaHub™,a proprietary warehouse of formatted, synthesized, and appraised clinical trial data. MetaWorks is a privately held company and currently serves more than 75 clients in the life sciences industry.

UBC delivers evidence-based services to enhance the medical and commercial potential of pharmaceuticals, biotechnology, medical devices and diagnostics. The company leverages a unique suite of scientific capabilities to demonstrate product effectiveness and safety, manage and minimize risk, document economic value, and secure appropriate third-party payment for prescription medicines and other medical technology.

"MetaWorks' scientific capabilities are on the forefront of decision-making in biopharmaceutical product development and commercialization," said UBC founder and CEO Ethan Leder. "Systematic literature reviews and meta-analyses help drug researchers identify precise scientific objectives before investing in costly clinical trials to test their hypotheses."

"UBC gives us the expanded reach, additional resources, and expertise we need to meet the growing demand for our analytic and consulting services and data products," said Shubh Sethi, MetaWorks President and CEO. Susan Ross, MD, MetaWorks' scientific co-founder, added, "By joining forces with UBC, we can take the pursuit of our mission – harnessing the power of data for health care – to a higher level than ever before".

The addition of MetaWorks is the latest in a series of acquisitions announced since UBC raised $153 million in equity capital from a syndicate of leading private equity firms. MetaWorks will join UBC's

Health Care Analytics Group

, formerly MEDTAP International, the company's team of world-recognized research scientists. The MetaWorks management team will assume leadership roles within UBC's

Health Care Analytics Group

. MetaWorks' operations will remain headquartered in Medford, MA.

About UBC

United BioSource Corporation (UBC) delivers evidence-based solutions to enhance the medical and commercial potential of pharmaceuticals, biotechnology, medical devices, and diagnostics. UBC is based in Bethesda, Maryland. For more information, visit www.unitedbiosource.com or call 240-644-0420.

About Metworks

MetaWorks® Inc. is an evidence-based consulting company focused on product development and commercialization within the biopharmaceutical, device, and health care industries. MetaWorks Inc is based in Medford, Massachusetts. For more information, visit

www.metaworksinc.com

.

Related Content:

News